Castle Biosciences, Inc. CSTL R2KR3KPHARMA
Company Overview
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Why Investors Should Care
Revenue has grown at a 47.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $344.23M (+3.7% YoY); net profit $-24.16M.
- Trailing 12 Months Year-on-year growth — revenue +20.1%, earnings -232.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 47.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 47.39% |
| 1 Year: | 20.10% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -232.41% |
Stock Price Performance
| 1 Year: | +69.55% |
| 6 Months: | +21.35% |
| 3 Months: | +56.64% |
| 1 Month: | +8.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 47.4% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CSTL Castle Biosciences, Inc. R2KR3KPHARMA | 32.91 | -51.42 | $1.01B | 0.00% | -8.40% | -4.20% | 47.39% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.66M | 3.98M | 3.71M | 11.44M | 8.72M | 10.74M | 14.77M | 17.64M | 17.42M | 12.71M | 15.22M | 17.30M | 22.81M | 22.76M | 23.48M | 26.85M | 34.84M | 37.01M | 42.04M | 50.14M | 61.49M | 72.97M | 87.00M | 85.78M | 87.99M | 86.19M | 83.04M | 83.68M | 103.55M |
| Gross Profit | 2.41M | 2.65M | 2.36M | 10.07M | 7.12M | 8.75M | 13.07M | 15.62M | 15.03M | 10.57M | 12.74M | 14.63M | 19.79M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -2.67M | -2.85M | - | -322.00K | 608.00K | 4.43M | - | 1.04M | -645.00K | -3.90M | - | -4.28M | -8.81M | -11.81M | -24.52M | -3.97M | -21.54M | -31.52M | -21.16M | -9.64M | -5.47M | 5.01M | 5.08M | -27.93M | -4.25M | -6.80M | -18.41M | -3.07M |
| Net Income | -3.63M | -3.15M | -3.45M | 3.87M | -1.36M | -1.27M | 5.85M | 2.06M | 570.00K | -1.38M | -4.59M | -4.89M | -4.28M | -8.79M | -11.79M | -24.62M | -1.65M | -20.25M | -29.20M | -18.78M | -6.91M | -2.53M | 8.92M | 2.27M | -25.85M | 4.52M | -501.00K | -14.52M | -2.06M |
| Diluted EPS | -2.37 | -2.15 | -2.33 | 0.38 | -1.22 | -1.05 | 0.05 | 0.11 | 0.03 | -0.08 | -0.23 | -0.23 | -0.17 | -0.35 | -0.47 | -0.97 | -0.06 | -0.77 | -1.10 | -0.70 | -0.26 | -0.09 | 0.31 | 0.08 | -0.90 | 0.15 | -0.02 | -0.49 | -0.07 |
| R&D Expense | - | 1.16M | 1.29M | - | 1.39M | 1.32M | 1.51M | - | 2.91M | 2.70M | 3.06M | - | 5.91M | 6.79M | 7.50M | 10.76M | 11.93M | 10.91M | 14.39M | 13.31M | 12.92M | 13.81M | 14.14M | 12.32M | 12.59M | 12.79M | 12.96M | 14.43M | 14.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.79M | 51.87M | 62.65M | 94.08M | 137.04M | 219.79M | 332.07M | 344.23M |
| Gross Profit | 17.49M | 44.55M | 52.96M | - | - | - | - | - |
| Operating Income | -3.84M | 7.33M | -6.54M | -40.08M | -72.86M | -67.98M | 8.67M | -42.81M |
| Net Income | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M | -24.16M |
| Diluted EPS | -5.33 | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 |
| R&D Expense | 4.85M | 7.38M | 13.26M | 29.65M | 44.90M | 53.62M | 52.04M | 51.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.41M | 119.75M | 439.33M | 462.57M | 447.33M | 453.34M | 531.24M | 578.56M |
| Total Equity | -50.31M | -56.57M | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M | 455.83M | 470.87M |
| Cash & Equivalents | - | 4.48M | 98.84M | 409.85M | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M |
| Long Term Debt | - | 24.50M | 19.29M | 0 | - | - | 0 | 9.74M | 9.64M |
| Total Liabilities | - | 32.48M | 34.63M | 23.64M | 50.83M | 48.18M | 62.07M | 75.40M | 107.68M |
| Current Liabilities | - | 6.74M | 15.29M | 20.88M | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.29M | 7.01M | 9.87M | -18.98M | -41.66M | -5.63M | 64.87M | 64.35M |
| Investing Cash Flow | -277.00K | -937.00K | -4.75M | -66.66M | -166.54M | -16.18M | -50.14M | -60.37M |
| Financing Cash Flow | 15.84M | 88.29M | 305.89M | 5.42M | 1.51M | -2.30M | 6.14M | -6.96M |
| Capital Expenditure | -277.00K | -937.00K | -4.75M | -3.48M | -5.63M | -13.62M | -28.33M | -36.02M |
| Free Cash Flow | -12.57M | 6.08M | 5.11M | -22.47M | -47.29M | -19.25M | 36.54M | 28.33M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.8% | 85.9% | 84.5% | - | - | - | - | - |
| Operating Margin % | -16.8% | 14.1% | -10.4% | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Net Margin % | -27.9% | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| ROE % | 11.3% | 6.2% | -2.5% | -7.6% | -16.8% | -14.7% | 4.0% | -5.1% |
| ROCE % | -24.5% | 7.0% | -1.6% | -9.2% | -17.7% | -16.8% | 1.8% | -8.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.78% | 3.29M | $110.28M |
| 2 | RTW Investments LP | 9.09% | 2.78M | $93.07M |
| 3 | Principal Financial Group, Inc. | 5.65% | 1.73M | $57.84M |
| 4 | Vanguard Capital Management LLC | 4.01% | 1.23M | $41.09M |
| 5 | Acadian Asset Management. LLC | 3.01% | 918.67K | $30.78M |
| 6 | Vanguard Portfolio Management LLC | 2.75% | 840.78K | $28.17M |
| 7 | Summit Partners Public Asset Management LLC | 2.70% | 824.87K | $27.63M |
| 8 | State Street Corporation | 2.69% | 822.08K | $27.54M |
| 9 | Allianz Asset Management GmbH | 2.66% | 811.32K | $27.18M |
| 10 | Geode Capital Management, LLC | 2.61% | 795.91K | $26.66M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CSTL
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPMjNNR2VhcWY1WS14RDEyMkZzNkYxTTdIWTVSU3ZMQnc1WjdoNU5kZVZBN2xPZVU5eDFzNE1LVHVXYV9rQ3JXdDVXeXhjdUx0S3lKbnpzTmZLbHFkbF9Ib01LTU5jUmRjN0tTS09IV2dOaUoxUmpwTjAxNjFWdVNrc2ZVemc1cTdjRFZ1aV…
Castle Biosciences, Inc. $CSTL Shares Sold by Bank of America Corp DE - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOYXFkd250U1J0NkdTLS11VDRzN2xMOXBxbjFkTndxTDVhVEU5QnhwTE5NRFlQVkZON3R6RFQteFRqMUI0SzFXNWVpVk92b2NITWZrYmZCdFYzXzBhNW9BNjRPNlJzSm41ZVNNRDNmWV82UkxuV0o4YXYzYjExT3liLU5CamQyR0RvcjE2Q2…
Insider Sale: Pres. & Chief Exec. Officer of $CSTL Sells 21 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPckdVa2c1OUxMRlllYWdieExzTGxKTHl0RFRSZDhSSkpaZ2JEWUZHOHlNVG9DSVZObTVERmdUbG1YS2RvZnozaktpLVFqeTRQSzhnRkcwc2xUTjB0OGZaZENHQWxqOWdJSW5JRWkxcms2ZWN1cTYtdGRGNDFYcVRadWZwZmVtajJwV0ZKeG…
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAwUUlrTl83NjRkVl9lYXQyVzN2R1FaaWd1ZnpmOFBrcFc0c1BZekJJZDkwZFhVcE1KeDI5RmV2S3RXQzIzdG14U2RLTzRLZFowMzlhT1h0UG12QmtRcHdYOF9paTZfd0l0UURGY21hSndfblBZUXo5QzBR?oc=5" target="_blank">CST…
Castle Biosciences will meet investors Sept. 10 and webcast a company overview Sept. 15 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOS0k0WlRoeDVaaG51cUloQnJYX3ZadFAxWFVZbkZIRmM4bEZaZThxel9icjMyVW5wck9RWVVlVV9pUXl0VWF6UXk0Tlg5c3lVaUNkanYzZk0tQ3dzem1ua3FLN1JESlJ1cXFGdnBpaThPcmJEUDllV1Jybnk1NmpaU29RNjhHMGZCcjNWTm…
Castle Biosciences (CSTL) Stock Climbs On Higher Sales Outlook Despite Margin Pressure - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOX2JMN2NubkI1cUdSQUZ5MU9GS19tZmNBS0pPUms2Rlc5aXJsbTN6Uk1TMzVWWURMajJacHdnQk9oWEp5X0tfaS1EdklCdjZ0NWEzazFIZGZCMl9RUEs1LWo4MzA4bW5UNUk0R2dXSXhJOWRYUTJPSHZGVGUxdzJXdmlQbUpiaXdwN0kzNF…
CSTL — Frequently Asked Questions
What is the current share price of Castle Biosciences, Inc. (CSTL)?
As of 2026-09-07 16:24 PDT, Castle Biosciences, Inc. (CSTL) trades at $32.91 on NasdaqGM. Its 52-week range is $18.15 to $43.04.
What is the market capitalisation of CSTL?
Castle Biosciences, Inc. (CSTL) has a market capitalisation of $1.01B on NasdaqGM.
What is the P/E ratio of CSTL?
CSTL trades at a trailing price-to-earnings (P/E) ratio of -51.42. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.08.
What is the return on equity (ROE) of CSTL?
CSTL has a return on equity (ROE) of -4.20%. Its return on capital employed (ROCE) is -8.40%.
Is CSTL a good stock to buy?
This page provides a data-driven analysis of Castle Biosciences, Inc. (CSTL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.